Angiosarcoma: Clinical and molecular insights

Annals of Surgery

Volumn 251, Issue 6, 2010, Pages 1098-1106

  Lahat, Guy ^a   Dhuka, Asha R ^a   Hallevi, Hen ^a   Xiao, Lianchun ^a   Zou, Changye ^a   Smith, Kerrington D ^a   Phung, Thuy L ^b   Pollock, Raphael E ^a   Benjamin, Robert ^a   Hunt, Kelly K ^a   Lazar, Alexander J ^a   Lev, Dina ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IMATINIB; INITIATION FACTOR 4E; INITIATION FACTOR 4E BINDING PROTEIN 1; INTERFERON; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; TAXANE DERIVATIVE; VASCULOTROPIN A; VASCULOTROPIN C;

ADOLESCENT; ADULT; AGED; ANGIOSARCOMA; ARTICLE; BREAST SARCOMA; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISTANT METASTASIS; EPITHELIOID SARCOMA; FEMALE; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME; TISSUE MICROARRAY; TUMOR VOLUME;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BENZAMIDES; COMBINED MODALITY THERAPY; DNA-BINDING PROTEINS; FEMALE; HEMANGIOSARCOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PHOSPHOPROTEINS; PHOSPHOTRANSFERASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 77953026137     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181dbb75a     Document Type: Article

References (45)

1. The National Institute of Health. Office of rare diseases. Available at: http://nih.gov/. Accessed March 15, 2009.
2. Antonescu CR. Targeted therapies in gastrointestinal stromal tumors. Semin Diagn Pathol. 2008;25:295-303.
3. Naka N, Ohsawa M, Tomita Y, et al. Prognostic factors in angiosarcoma: a multivariate analysis of 55 cases. J Surg Oncol. 1996;61:170-176.
4. Fury MG, Antonescu CR, Van Zee KJ, et al. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J. 2005;11:241-247.
5. Fayette J, Martin E, Piperno-Neumann S, et al. Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol. 2007;18:2030-2036.
6. Otis CN, Peschel R, McKhann C, et al. The rapid onset of cutaneous angiosarcoma after radiotherapy for breast carcinoma. Cancer. 1986;57: 2130-2134.
7. Benda JA, Al-Jurf AS, Benson AB III. Angiosarcoma of the breast following segmental mastectomy complicated by lymphedema. Am J Clin Pathol. 1987;87:651-655.
8. Espat NJ, Lewis JJ, Woodruff JM, et al. Confirmed angiosarcoma: prognostic factors and outcome in 50 prospectively followed patients. Sarcoma. 2000; 4:173-177.
9. Rubin BP, Fletcher CD, Inwards C, et al. Protocol for the examination of specimens from patients with soft tissue tumors of intermediate malignant potential, malignant soft tissue tumors, and benign/locally aggressive and malignant bone tumors. Arch Pathol Lab Med. 2006;130:1616-1629.
10. Flecther CD, Unni KK, Mertens F, eds. World health Organization. Classification of Tumors. Pathology and Genetics of Tumors of Soft Tissue and Bone. Lyon, France: IARC Press; 2002.
11. Deyrup AT, McKenney JK, Tighiouart M, et al. Sporadic cutaneous angio-sarcomas: a proposal for risk stratification based on 69 cases. Am J Surg Pathol. 2008;32:72-77.
12. Jin Z, Lahat G, Korchin B, et al. Midkine enhances soft-tissue sarcoma growth: a possible novel therapeutic target. Clin Cancer Res. 2008;14:5033-5042.
13. Lahat G, Lazar A, Wang X, et al. Increased vascular endothelial growth factor-C expression is insufficient to induce lymphatic metastasis in human soft-tissue sarcomas. Clin Cancer Res. 2009;15:2637-2646.
14. Zou CY, Smith KD, Zhu QS, et al. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor. Mol Cancer Ther. In press.
15. Lahat G, Tuvin D, Wei C, et al. New perspectives for staging and prognosis in soft tissue sarcoma. Ann Surg Oncol. 2008;15:2739-2748.
16. Vorburger SA, Xing Y, Hunt KK, et al. Angiosarcoma of the breast. Cancer. 2005;104:2682-2688.
17. Abraham JA, Hornicek FJ, Kaufman AM, et al. Treatment and outcome of 82 patients with angiosarcoma. Ann Surg Oncol. 2007;14:1953-1967.
18. Penel N, Mallet Y, Robin YM, et al. Prognostic factors for adult sarcomas of head and neck. Int J Oral Maxillofac Surg. 2008;37:428-432.
19. Penel N, Bui BN, Bay JO, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX study. J Clin Oncol. 2008;26: 5269-5274.
20. Skubitz KM. A phase I study of ambulatory continuous infusion paclitaxel. Anticancer Drugs. 1997;8:823-828.
21. Fata F, O'Reilly E, Ilson D, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer. 1999;86:2034-2037.
22. Casper ES, Waltzman RJ, Schwartz GK, et al. Phase II trial of paclitaxel in patients with soft-tissue sarcoma. Cancer Invest. 1998;16:442-446.
23. Pigott C, Welker M, Khosla P, et al. Improved outcome with multimodality therapy in primary cardiac angiosarcoma. Nat Clin Pract Oncol. 2008;5:112-115.
24. Stokes MC, Bennett J, Beech DJ, et al. Angiosarcoma of the scalp. Am Surg. 2008;74:1228-1230.
25. Billings SD, McKenney JK, Folpe AL, et al. Cutaneous angiosarcoma following breast-conserving surgery and radiation: an analysis of 27 cases. Am J Surg Pathol. 2004;28:781-788.
26. Deyrup AT, Weiss SW. Grading of soft tissue sarcomas: the challenge of providing precise information in an imprecise world. Histopathology. 2006; 48:42-50.
27. Nascimento AF, Raut CP, Fletcher CD. Primary angiosarcoma of the breast: clinicopathologic analysis of 49 cases, suggesting that grade is not prognostic. Am J Surg Pathol. 2008;32:1896-1904.
28. Fletcher CD. Vascular tumors: an update with emphasis on the diagnosis of angiosarcoma and borderline vascular neoplasms. Monogr Pathol. 1996;38: 181-206.
29. Camp RL, Neumeister V, Rimm DL. A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J Clin Oncol. 2008;26: 5630-5637.
30. Tomasello L, Gardin G, Boccardo F. Secondary breast angiosarcoma: lethal response to anti-angiogenic therapy with paclitaxel chemotherapy. A case report. Anticancer Res. 2006;26:4775-4777.
31. Hashimoto M, Ohsawa M, Ohnishi A, et al. Expression of vascular endothe-lial growth factor and its receptor mRNA in angiosarcoma. Lab Invest. 1995;73:859-863.
32. Koontz BF, Miles EF, Rubio MA, et al. Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies. Head Neck. 2008;30:262-266.
33. Kuwai T, Nakamura T, Sasaki T, et al. Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors. Neoplasia. 2008;10:489-500.
34. Miettinen M, Sarlomo-Rikala M, Lasota J. KIT expression in angiosarcomas and fetal endothelial cells: lack of mutations of exon 11 and exon 17 of C-kit. Mod Pathol. 2000;13:536-541.
35. Lammie A, Drobnjak M, Gerald W, et al. Expression of c-kit and kit ligand proteins in normal human tissues. J Histochem Cytochem. 1994;42:1417-1425.
36. Kiesel H, Muller AM, Schmitt-Graeff A, et al. Dramatic and durable efficacy of imatinib in an advanced angiosarcoma without detectable KIT and PDG-FRA mutations. Cancer Biol Ther. 2009;8:319-321.
37. Chang HW, Aoki M, Fruman D, et al. Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science. 1997;276:1848-1850.
38. Aoki M, Batista O, Bellacosa A, et al. The akt kinase: molecular determinants of oncogenicity. Proc Natl Acad Sci USA. 1998;95:14950-14955.
39. Perry B, Banyard J, McLaughlin ER, et al. AKT1 overexpression in endo-thelial cells leads to the development of cutaneous vascular malformations in vivo. Arch Dermatol. 2007;143:504-506.
40. Phung TL, Ziv K, Dabydeen D, et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell. 2006;10: 159-170.
41. Dickerson EB, Thomas R, Fosmire SP, et al. Mutations of phosphatase and tensin homolog deleted from chromosome 10 in canine hemangiosarcoma. Vet Pathol. 2005;42:618-632.
42. Paik JH, Kollipara R, Chu G, et al. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell. 2007;128: 309-323.
43. Zou C, Smith KD, Zhu QS, et al. Dual targeting of AKT and mammalian target of Rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor. Mol Cancer Ther. In press.
44. Abraham RT. Identification of TOR signaling complexes: more TORC for the cell growth engine. Cell. 2002;4:9-12.
45. Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends Mol Med. 2005;11:353-361.